Clinical impact of immunomonitoring in the treatment of inflammatory bowel disease

Table 3 Relationship between infliximab trough levels and response rates

Ref.	n	Mean IFX trough levels ug/mL	Mean IFX trough levels ug/mL	P value
		Lost response	Maintained response
Ainsworth et al[34]	27	0 (0-0.1)	2.9 (0.9-4.3)	0.002
Yamada et al[35]	31 (CD)	6.3	4.7	NS
Steenholdt et al[33]	69 (CD)	N/A	2.8 (0.8-5.3)	< 0.0001
Pariente et al[36]	76 (CD)	3.3 ± 4.1	2.3 ± 2.2	NS
Steenholdt et al[33]	13 (UC)	N/A	3.8 (1.1-8.5)	< 0.0001
Karmiris et al[37]	136 (CD)	0.3 (0.3-3.6)	4.9 (1.7-8.2)	0.01
Marits et al[38]	79 (CD)	1.8	4.1	< 0.001
Bortlik et al[39]	84 (CD)	N/A	> 3	N/A
Adedokun et al[40]	728 (UC)	N/A	3.7	N/A
Cornillie et al[41]	147 (CD)	1.9	4.0	0.0331
Reinisch et al[42]	203 (CD)	0.8	2.14	0.006

IFX: Infliximab; UC: Ulcerative colitis; CD: Crohn’s disease.